 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Immunome to presents preclinical data for IM-3050 at AACR

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for...

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

This indicator may be signaling that IMNM's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Immunome (IMNM, $22.1) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

Immunome price target raised by $6 at Wedbush, here's why

Immunome, Inc. (NASDAQ:IMNM  Free Report)  Leerink Partnrs lifted their Q1 2024 EPS estimates for Immunome in a research note issued to investors on Tuesday, March 26th. Leerink Partnrs...

Leerink Partnrs Weighs in on Immunome, Inc.'s Q1 2024 Earnings (NASDAQ:IMNM)

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQV Research Report), United Therapeutics...

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM)

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of...

IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Immunome (IMNM Research Report) today. The company's shares closed today at $24.68. V...

TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)

Immunome, Inc. (NASDAQ:IMNM  Get Free Report)s stock price dropped 3.7% on Thursday . The company traded as low as $24.31 and last traded at $24.58. Approximately 47,250 shares traded...

Immunome (NASDAQ:IMNM)  Shares Down 3.7%

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended...

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Volume (M)	852,764.00
52-Wk High	$30.96
52-Wk Low	$4.44

IMNM Immunome Inc

About

Feed

News

Sentiment

Earnings

Fundamentals